CVS Settles for $37.76 Million in Healthcare Fraud Lawsuit Over Insulin Pen Over-Dispensing
CVS will pay $37.76 million to settle a lawsuit alleging fraudulent over-dispensing of insulin pens to patients in government healthcare programs.Summary
CVS has agreed to a $37.76 million settlement to resolve a healthcare fraud lawsuit concerning the over-dispensing of insulin pens between 2010 and 2020. The lawsuit alleged that CVS pharmacies submitted improper reimbursement claims by issuing early refills, dispensing excessive insulin, and inaccurately reporting days-of-supply. These practices resulted in inflated payments from insurers, diverting funds from government healthcare programs.
U.S. Attorney Jay Clayton stated that CVS “repeatedly refilled insulin prescriptions prematurely over a period of ten years and billed government healthcare programs for more insulin than patients required.” The settlement requires CVS to pay $24,446,240 to the United States, with the remaining funds distributed to various states to reimburse affected programs.
Officials from the Department of Health and Human Services, the Department of Defense, and the Office of Personnel Management emphasized the importance of protecting the federal healthcare system and its enrollees. The case underscores the need for compliance with healthcare regulations and highlights the consequences of fraudulent billing practices.
(Source：Hoodline)